

May 13-15, 2025 | Boston, MA
www.precision-medicine-in-ibd.com

LIMITED TICKETS
REMAINING



3rd Annual

Precision Medicine in Inflammatory Bowel Disease Summit

Deliver Safe & Effective Precision Therapies to Every IBD Patient

Enhance Stratification, Response Rate & Efficacy of IBD Therapies for Unmet Patient Needs with Advances in Multi-Omics, AI & Clinically Validated Biomarkers

Expert Speakers Include:



Judy Chou
President & CEO
AltruBio



Sarah Grant
Vice President & Head, Early Clinical Development, Respiratory & Immunology
AstraZeneca



Stefan Schreiber
Professor of Medicine & Director, Department of Internal Medicine
University Hospital Schleswig-Holstein (UKSH) at Kiel University



Joshua Friedman
Senior Vice President, Clinical Development
Spyre Therapeutics



Raj Kamath
Executive Director
Merck & Co.



Ilan Wapinski
Head of Biomarkers & Patient Stratification
Sanofi

Proud to Partner With:



+1 617 455 4188 @ info@hansonwade.com

www.precision-medicine-in-ibd.com Companion Diagnostics



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Welcome to the 3rd Precision Medicine in Inflammatory Bowel Disease Summit




Precision Medicine in Inflammatory Bowel Disease Summit
May 13-15, 2025 | Boston, MA

Patients with inflammatory bowel disease (IBD) face limited treatment options, which lack efficacy, driven by the heterogeneous nature of the disease. However, transformative advancements in disease understanding, AI-powered biomarker development, patient stratification, and advanced monitoring technologies are paving the way for a new era of precision IBD therapies for patients with unmet needs.

Returning as the definitive meeting for industry and academic leaders, the **3rd Precision Medicine in Inflammatory Bowel Disease Summit** provides an unparalleled opportunity to explore groundbreaking advancements in IBD drug development, refine precision medicine strategies, and accelerate the development of transformative treatments – ensuring the right drug reaches the right patient, at the right time.

This year's program has been curated with insights from 25+ world-class speakers from the likes of **AstraZeneca, Genentech, Regeneron** and **Palatin Technologies**, showcasing the latest data and advances in IBD therapeutic development, including:

-  **Refining models and proof-of-concept studies** to reduce clinical trial failure rates and improve translational outcomes for better treatments for patients
-  **Innovating treatment pathways** to optimize safety and efficacy in precision medicine for IBD with actionable non-clinical and clinical insights and case studies
-  **Minimizing adverse events** whilst enhancing therapeutic synergies by refining combination therapy strategies through data-informed drug pairings
-  **Leveraging emerging therapeutic modalities** and their potential to reshape IBD treatment strategies to refine patient selection and optimize therapeutic outcomes

Join **precision medicine, diagnostics, translational, clinical, computational biology, gastrointestinal** and **inflammation** specialists to gain unmatched insights and form new connections, enabling you to stay at the forefront of innovation and drive meaningful progress toward truly effective care for patients with **Ulcerative Colitis, Crohn's Disease** and **beyond**.

Hear from Previous Attendees:

■ ■ Intimate and the content was all very relevant. The networking sessions were great to get to know the other participants ■ ■

Senior Vice President, Drug Discovery



■ ■ Good talks, science, and an opportunity to learn about specifics of drug development in IBD ■ ■

Director, Research Alliances



KEY BENEFITS OF ATTENDING



Overcome IBD heterogeneity with **digital pathology and spatial biology**, enhancing patient stratification and revealing actionable molecular targets to drive therapeutic breakthroughs, with insights from **Ostuka Pharma & Bristol Myers Squibb**



Improve Efficacy with **diagnostic biomarkers** to refine **patient subtyping** to ensure the **right patient** gets the **right drug** at the **right time**, by **Sanofi & Merck & Co.**



Revolutionize clinical monitoring with advanced **ultrasound technology and AI-driven imaging tools**, enabling **non-invasive surveillance** to enhance clinical decision-making, with key learnings from **Pfizer & Crohn's & Colitis Foundation**



Discover novel therapeutic targets and mechanisms of action, unlocking unprecedented opportunities to deliver transformative treatments and elevate standards of care, leveraging expertise from **ThirtyFiveBio & AnaptysBio**



Unleash the potential of combination therapies to amplify treatment **efficacy**, **minimize adverse effects**, and deliver synergistic solutions for more personalized and effective patient care, shaped by analysis from **Spyre Therapeutics & Takeda**

What's New for 2025



Precision Medicine in Inflammatory
Bowel Disease Summit

May 13-15, 2025 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



**New Speakers
Bringing Fresh
Perspectives:**
Hear from industry
leaders new to this
meeting, sharing
innovative insights and
breakthroughs in IBD
precision medicine

**14 Companies Presenting at
this Conference for the Very
First Time, Including:**



140+ Reasons to Attend

- 80+ Attendees:** Fostering an intimate environment for you to connect with the who's-who from the precision medicine in IBD field
- 25+ Expert Speakers:** Learn from the foremost leaders shaping the future of precision medicine in IBD and driving developments across the field
- 20+ Groundbreaking Presentations:** Gain exclusive updates on clinical trials, cutting-edge technologies, biomarker breakthroughs, and more
- 10+ Hours of Networking:** Connect with the brightest minds and most influential leaders driving innovation in precision medicine for IBD
- 2 Transformative Panel Discussions:** Explore fresh perspectives on IBD care and address critical gaps for patients with unmet needs
- 2 Interactive Roundtable Discussions:** Share your expertise, exchange ideas, and help shape the future of precision medicine in IBD
- 1 Pre-Conference Focus Day:** Join your peers at the **Technology Innovations in IBD** focus day, where we will be bringing you the hottest developments, from ultra-sound technology to digital pathology

New Session Spotlights



Using Ultrasound to Non-Invasively Monitor Patient Progress for Enhanced Clinical Decision Making

Sarah Sidhu, Global Medical Director, Gastroenterology, **Pfizer**

Leveraging Multi-Omics to Uncover Deeper Insights into IBD Morphology for Improved Patient Subtyping

Ilan Wapinski, Head, Biomarkers & Patient Stratification, **Sanofi**



Unlocking the Potential of Tulisokibart & Harnessing Biomarkers to Elevate Response Rate for Therapeutics in IBD

Raj Kamath, Executive Director, **Merck & Co.**

Individual Response Trajectories in IBD Defines Patent Clusters for Precision Medicine

Stefan Schreiber, Professor of Medicine, Director Department of Internal Medicine, University Hospital Schleswig-Holstein (UKSH), **Kiel University**




Advancing Combination Therapies to Change the Treatment Paradigm in IBD

Joshua Friedman, Senior Vice President, Clinical Development, **Spyre Therapeutics**

Targeting CCR9: Advancing Precision Therapies for Inflammatory Bowel Disease

Sarah Grant, Vice President & Head, Early Clinical Development, Respiratory & Immunology, **AstraZeneca**



Showcase Your Scientific Poster



We are inviting experts from biopharma to share their latest hypotheses, findings or data in a dedicated poster session. This is your chance to present your work amongst the leaders of the space, and pose questions to your peers.

Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

Your Expert Speakers



Precision Medicine in Inflammatory
Bowel Disease Summit

May 13-15, 2025 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



AMGEN

Laurence Cheng

Executive Director &
Precision Medicine
Therapeutic Area Head,
Inflammation & Rare
Disease
Amgen



ALTRUBIO

Judy Chou

President & CEO
AltruBio



AnaptysBio

Bryan Linggi

Senior Director,
Translational Research
AnaptysBio



AstraZeneca

Sarah Grant

Vice President &
Head, Early Clinical
Development,
Respiratory &
Immunology
AstraZeneca



C4X Discovery

**Neil Humphries-
Kirilov**

Associate Director,
Human Genomics
C4X Discovery



DEKA

John Brian Mumm

President & CEO
Deka Biosciences



CROHN'S & COLITIS
FOUNDATION

Ben Kostiuk

Director, Life Science
Partnerships
**Crohn's and Colitis
Foundation**



Genentech

Steven Levitte

Medical Director,
Product Development,
Gastroenterology
Hepatology &
Metabolism
Genentech



London Health Sciences Centre

Eileen Crowley

Assistant Professor
& Pediatric
Gastroenterologist,
Clinician Researcher
**London Health
Sciences Centre**



MERCK

Raj Kamath

Executive Director
Merck & Co.



nference

Jason Maron

Senior Director,
Partnerships
Nference



Orphagen Pharmaceuticals

Scott Thacher

CEO & Founder
**Orphagen
Pharmaceuticals**



Otsuka

Gerard Honig

Associate Director,
Biomarker Research
Otsuka Pharma



PALATIN

Paul Kayne

Vice President,
Biological Sciences
Palatin Technologies



palisadebio

Joerg Heyer

Head of Translational
Science & Medicine
Palisade Bio



Perspectum

Reema Kainth

Product Specialist,
Digital Pathology &
Endoscopy
Perspectum



Pfizer

Mohamed Hassanein

Director, Translational
Medicine
Pfizer



Pfizer

Sarah Sidhu

Global Medical Director,
Gastroenterology
Pfizer



sanofi

Ilan Wapinski

Head, Biomarkers &
Patient Stratification
Sanofi



SPYRE
THERAPEUTICS

Joshua Friedman

Senior Vice President,
Clinical Development
Spyre Therapeutics



Takeda

**Vinayagam
Arunachalam**

Director & Head,
Computational &
Systems Biology, Early
Clinical Development,
GI2-TAU
Takeda



Takeda

Pratik Panchal

Head, Translational
Medicine
Takeda



ThirtyFiveBio

Josselin Caradec

Head, Biology
ThirtyFiveBio




CIAU

Stefan Schreiber

Professor of Medicine,
Director Department
of Internal Medicine,
University Hospital
Schleswig-Holstein
(UKSH)
Kiel University



Technology Innovations in IBD Pre-Conference Focus Day Tuesday, May 13, 2025

 Precision Medicine in Inflammatory
Bowel Disease Summit
May 13-15, 2025 | Boston, MA

Discover how AI and advanced technologies are transforming IBD therapeutic development through refined patient subtyping, optimized diagnostics, and enhanced clinical trial outcomes. This focus day delves into cutting-edge innovations, including digital pathology, spatial biology, and imaging tools, that are driving therapeutic breakthroughs and improving clinical decision-making. With expert-led sessions and unique networking opportunities, this is your chance to stay ahead of the curve in precision medicine and shape the future of IBD treatment by bringing better drugs to patients faster.



8.00 Check-In & Light Breakfast

8.50 Chair's Opening Remarks

Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient Outcomes



Steven Levitte
Medical Director,
Product Development,
Gastroenterology
Hepatology &
Metabolism
Genentech
NEW COMPANY

9.00 **Harnessing Novel AI & ML Tools to Revolutionize Patient Diagnostics for Unparalleled Personalized Therapy Opportunities**

- Leveraging AI-driven algorithms for standardized ME score calculation and enhancing efficiency in clinical trial operations
- The potential for AI to streamline trial endpoints and address screen failures in IBD studies
- Exploring regulatory challenges and the need for cross-industry collaboration to advance AI and CDx adoption



Joerg Heyer
Head of Translational
Science & Medicine
Palisade Bio
NEW COMPANY

9.30 **Improving Patient Subtyping with AI-Driven Insights to Unlock Better Insights into IBD Heterogeneity & Smash the Efficacy Ceiling**

- Utilizing AI to refine patient subtypes based on molecular and clinical profiles
- Enhancing therapeutic targeting by bridging IBD heterogeneity gaps
- Discovering hidden subgroups to drive better therapy alignment



10.00 Morning Networking Break

Harnessing AI & Data Integration to Optimize Combination Therapies & Enhance Predictive Accuracy in IBD Care



Vinayagam Arunachalam
Director & Head,
Computational &
Systems Biology, Early
Clinical Development,
GI2-TAU
Takeda

11.00 **Optimizing Drug Combination Strategies with AI Insights to Enhance Efficacy & Minimize Risks in IBD Treatment**

- Predicting optimal drug combinations for better patient outcomes
- Minimizing adverse events by refining combination therapy strategies
- Enhancing therapeutic synergies through data-informed drug pairings

Roundtable Moderator:


11.30 **Roundtable Discussion: Revolutionizing Data Integration & Processing Pipelines to Maximize AI-Powered Predictive Accuracy in IBD Care**

- How can pipelines be streamlined to integrate diverse patient datasets?
- Enhancing predictive accuracy by reducing noise in data processing
- Improving patient outcomes by leveraging advanced analytics



12.30 Lunch Break & Networking

Technology Innovations in IBD Pre-Conference Focus Day Tuesday, May 13, 2025

 Precision Medicine in Inflammatory
Bowel Disease Summit
May 13-15, 2025 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Leveraging Digital Pathology & Spatial Transcriptomics to Unlock Deeper Molecular Insights & Drive Precision Care in Crohn's & Colitis




Gerard Honig
Associate Director,
Biomarker Research
Otsuka Pharma
NEW COMPANY

1.30

Integrating Spatial Biology & Digital Pathology to Reveal Hidden Patterns & Revolutionize IBD Therapeutics

- Combining digital pathology and spatial transcriptomics for better stratification
- Can biopharma identify actionable molecular targets through spatial mapping?
- Driving therapeutic innovations using integrated molecular insights



Steven Levitte
Medical Director,
Product Development,
Gastroenterology
Hepatology &
Metabolism
Genentech
NEW COMPANY

2.00

Roundtable Discussion: Overcoming IBD Heterogeneity with AI-Driven Digital Pathology & Radiology to Optimize Patient Subtyping & Outcomes


- AI to refine patient subtypes based on molecular and clinical profiles
- Enhancing therapeutic targeting by bridging IBD heterogeneity gaps
- Discovering hidden subgroups to drive better therapy alignment



2.30

Afternoon Networking Break

Advancing Non-Invasive Imaging Technologies to Optimize Patient Monitoring & Treatment Strategies in IBD




Sarah Sidhu
Global Medical Director,
Gastroenterology
Pfizer

3.30

Using Ultrasound to Non-Invasively Monitor Patient Progress for Enhanced Clinical Decision Making

- Exploring the use of ultrasound for real-time, non-invasive assessment of therapeutic efficacy in preclinical and clinical settings
- Investigating the role of advanced imaging biomarkers to inform and refine drug development strategies
- Integrating ultrasound technologies into longitudinal monitoring frameworks to improve patient stratification and treatment optimization



John Brian Mumm
President & CEO
Deka Biosciences

4.00

Therapeutically Restoring the IL-10 Circuit in Crohn's Patients

- People who lack sufficient IL-10 signalling develop Crohn's disease
- Inflammation is complex, driven by hyper inflammatory monocytes and pathogenic Th1/Th17 T cells
- DK410 (VEGFR2) combines IL-10 to block monocytic inflammation and IL-4 to block Th1/Th17 polarization and enriches the cytokines in the neovasculature driven by chronic inflammation

4.30 **Chair's Closing Remarks**


4.40 **End of Pre-Conference Focus Day**

■ The data from the presentations were of very high standard and discussions around those presentations were spontaneous and lively ■

Past Attendee, Director, Precision Medicine & Immunology, **AbbVie**

Conference Day One

Wednesday, May 14, 2025

 Precision Medicine in Inflammatory
Bowel Disease Summit
May 13-15, 2025 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Check-In & Light Breakfast



John Brian Mumm
President & CEO
Deka Biosciences

8.50 Chair's Opening Remarks

Decoding IBD Heterogeneity with Better Diagnosis for Enhanced Patient Subtyping to Improve Patient Safety & Response Rate in Clinical Trials



Ilan Wapinski
Head, Biomarkers &
Patient Stratification
Sanofi

NEW COMPANY

9.00 Leveraging Multi-Omics to Uncover Deeper Insights into IBD Heterogeneity for Improved Patient Subtyping

- How to integrate transcriptomics across diverse cohorts for granular patient subtyping
- Identifying novel markers linked to inflammation signatures to enhance clinical trial outcomes
- How to bridge gaps between phenotypic data and actionable therapeutic strategies in IBD



Raj Kamath
Executive Director
Merck & Co.

9.30 Unlocking the Potential of Tulisokibart & Harnessing Biomarkers to Elevate Response Rate for Therapeutics in IBD

- Sharing insights from the integration of a diagnostic tool in a phase II trial, highlighting successes, challenges, and learnings from its development
- Discussing the role of patient stratification in advancing therapeutic precision and optimizing treatment pathways for IBD
- Exploring the future potential of diagnostic innovations in clinical trials and their role in shaping precision medicine strategies



10.00 Morning Speed Networking Break

As the Precision Medicine and IBD community come together, this valuable session offers the perfect opportunity to connect with peers and build meaningful relationships. Attendees will have the chance to meet, network, and collaborate with industry leaders driving innovation in IBD care.

Harnessing Prognostic Biomarkers & Monitoring Tools to Enable Personalized Treatment Plans & Revolutionize Therapeutic Efficacy



Stefan Schreiber
Professor of Medicine,
Director Department
of Internal Medicine,
University Hospital
Schleswig-Holstein
(UKSH)
Kiel University

NEW COMPANY

11.00 Individual Response Trajectories in IBD Defines Patient Clusters for Precision Medicine

- Large level of individual heterogeneity in patients with IBD including therapy responses
- Response dynamics cluster patients into new subpopulations
- Difference in clinical therapy response are underlaid by biomarker profiles



Jason Maron
Senior Director,
Partnerships
Nference

11.30 Advancing IBD Precision Therapy Through Multimodal Real-World Data & Agentic AI

- Leveraging expansive patient volumes and deep longitudinal data to identify actionable patterns in IBD
- Harnessing Multimodal AI to integrate clinical, imaging, and molecular data for actionable IBD insights
- Highlighting real-world case studies that illustrate the clinical and research impact of AI-powered analyses

Roundtable Moderator:



Stefan Schreiber
Professor of Medicine,
Director Department
of Internal Medicine,
University Hospital
Schleswig-Holstein
(UKSH)
Kiel University

12.00 Roundtable Discussion: Advancing Disease Prediction through the Development & Validation of Prognostic Biomarkers for Personalized IBD Treatments

- What is the clinical utility of biomarkers in predicting disease course?
- Can biopharma identify immune profiles linked to patient outcomes in early IBD stages?
- How can we accelerate the validation of biomarkers to enhance treatment efficacy?



12.30 Lunch Break & Networking



+1 617 455 4188

@ info@hansonwade.com

www.precision-medicine-in-ibd.com

Companion Diagnostics



Conference Day One

Wednesday, May 14, 2025



Precision Medicine in Inflammatory
Bowel Disease Summit
May 13-15, 2025 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Bridging Innovation & Implementation: Driving Precision Medicine Forward in IBD Through Data, Technology & Translational Science



Ben Kostiuk
Director, Life Science
Partnerships
**Crohn's & Colitis
Foundation**
NEW COMPANY

1.30 Precision Medicine Meets the Real World: Lessons from IBD Plexus

- SPARC IBD is a real world study that follows the natural history of disease for over 6000 IBD patients
- In this presentation, we show the touch points that patients have with the health care system as well as other landmarks in their disease journey
- These interactions are opportunities to learn more about patients or apply treatment strategies in the pursuit of precision medicine



Reema Kainth
Product Specialist,
Digital Pathology &
Endoscopy
Perspectrum

2.00 Digital Pathology & Endoscopy in IBD Central Reads: Streamlining Clinical Trials

- Centralized Reads: Centralized review of medical images and videos by expert readers in IBD clinical trials
- Quality Control and Consistency: High-quality results by applying standardized protocols and advanced image analysis tools
- Optimized Workflow: Integrating a customizable workflow to optimize clinical trial design and maximise outcomes



Scott Thacher
CEO & Founder
**Orphagen
Pharmaceuticals**

2.10 A Novel, Pleiotropic Oral Drug Class that Blocks Gut Migration of Activated T Cells

- Antagonists to retinoic acid receptor-alpha (RAR α) block upregulation of $\alpha 4\beta 7$ and CCR9 during T cell activation in mesenteric lymph nodes
- Daily oral dosing of an RAR α antagonist inhibits intestinal epithelial damage in a mouse model of colitis. In separate models, inflammatory T cell migration to the intestinal lining is also suppressed
- Preclinical safety findings for the highly selective RAR α antagonist OR-812 support further development



2.40 Poster Session & Networking

Join the Precision Medicine and IBD community in this interactive session, showcasing pioneering research and innovative approaches in IBD care. Attendees will have the chance to share their work, engage with their peers, and discuss advancements shaping the future of precision medicine for IBD.

Transforming IBD Treatment with Optimized Combination Therapies & Emerging Precision Modalities to Offer More Efficacious Therapeutics

3.30 Panel Discussion: Future Horizons in Precision Medicine: Exploring New Modalities & Technologies for IBD

- Discussing emerging therapeutic modalities and their potential to reshape IBD treatment strategies
- Identifying critical challenges and opportunities in developing precision medicine approaches
- Envisioning the integration of novel technologies to improve patient outcomes and drive innovation
- How will combination therapies shape the future of treatments for IBD?



Laurence Cheng
Executive Director & Precision
Medicine Therapeutic Area
Head, Inflammation and Rare
Disease
Amgen



Neil Humphryes-Kirilov
Associate Director,
Human Genomics
C4X Discovery



Ben Kostiuk
Director, Life
Science
Partnerships
**Crohn's & Colitis
Foundation**



John Brian Mumm
President & CEO
Deka Biosciences



Joshua Friedman
Senior Vice President,
Clinical Development
Spyre Therapeutics
NEW COMPANY

4.30 Advancing Combination Therapies to Change the Treatment Paradigm in IBD

- Scientific and clinical rationale for targeting $\alpha 4\beta 7$, TL1A, and IL-23 pathways in IBD therapy
- Nonclinical data demonstrating enhanced efficacy and extended half-life of biologics for combination treatments
- Addressing the natural questions around patient selection for combination therapies: early hypotheses and future directions



John Brian Mumm
President & CEO
Deka Biosciences

5.00 Chair's Closing Remarks

5.05 End of Conference Day One



+1 617 455 4188

@ info@hansonwade.com



www.precision-medicine-in-ibd.com




Companion Diagnostics



Conference Day Two

Thursday, May 15, 2025

 Precision Medicine in Inflammatory
Bowel Disease Summit
May 13-15, 2025 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Light Breakfast & Morning Networking



Paul Kayne
Vice President,
Biological Sciences
Palatin Technologies

8.55 Chair's Opening Remarks

Targeting Unmet Areas for Transformative Therapies & Reversal of Disease Progression



Eileen Crowley
Assistant Professor &
Director, Pediatric IBD
Centre
**London Health
Sciences Centre**

NEW COMPANY

9.00 Refining Patient Stratification & Tailoring Pediatric Therapies to Transform IBD Care

- Exploring age-specific markers for optimized pediatric IBD management
- Advancing therapeutic approaches to address pediatric-specific challenges in IBD
- Developing stratification protocols for personalized treatments in pediatric patients

9.30 **Panel Discussion: Enhancing Precision Medicine & Optimizing Stratification to Deliver Effective Fibrosis Therapies**

- Refining stratification approaches to identify high-risk patients for fibrosis
- Tailoring therapies based on molecular and genetic fibrosis profiles
- Can biopharma harness stratification tools to improve therapy outcomes and efficiency?



Pratik Panchal
Head, Translational Medicine
Takeda



Mohamed Hassanein
Director, Translational Medicine
Pfizer



Raj Kamath
Executive Director
Merck & Co.



10.00 Morning Networking Break

Supercharging IBD Treatment with Novel Therapeutic Pathways to Deliver Superior & Transformative Patient Care



Bryan Linggi
Senior Director,
Translational Research
AnaptysBio

NEW COMPANY

11.00 Harnessing PD-1 Agonists for Novel Therapeutic Approaches in Autoimmune Diseases

- Exploring the novel mechanism of PD-1 agonists in T-cell modulation to treat autoimmune diseases
- Leveraging biomarker data to refine patient selection and optimize therapeutic outcomes
- Integrating translational research insights into clinical strategy for ulcerative colitis and other inflammatory conditions (RA)



Judy Chou
President & CEO
AltruBio

11.30 Development of a Novel Immune Checkpoint Enhancer as a Potential Therapeutic Medicine for Ulcerative Colitis

- An in-depth exploration for the capacity of emerging approaches regarding non-immune cells to revolutionize our understanding of IBD
- Exploring the capacity for precision medicine strategies target these unconventional players to open new avenues for IBD treatment innovation



Sarah Grant
Vice President &
Head, Early Clinical
Development,
Respiratory &
Immunology
AstraZeneca

NEW COMPANY

12.00 Targeting CCR9: Advancing Precision Therapies for Inflammatory Bowel Disease

- Leveraging CCR9 inhibition to improve therapeutic targeting and address IBD heterogeneities
- Exploring clinical outcomes and patient stratification strategies for CCR9-targeted therapies
- Innovating treatment pathways to optimize safety and efficacy in precision medicine for IBD



+1 617 455 4188

@ info@hansonwade.com


www.precision-medicine-in-ibd.com

Companion Diagnostics



Conference Day Two

Thursday, May 15, 2025

 Precision Medicine in Inflammatory
Bowel Disease Summit
May 13-15, 2025 | Boston, MA



12.30 Lunch Break & Networking

Deciphering Novel Targets & Preclinical Models to Accelerate Precision IBD Therapies & Enhance Clinical Success



Josselin Caradec
Head, Biology
ThirtyFiveBio
NEW COMPANY

1.30 Deciphering GPR35: A Novel Target for Epithelial-Driven Therapeutics in IBD

- Unravelling the role of GPR35 in epithelial biology to address inflammatory bowel disease progression
- Investigating the therapeutic potential of GPR35 antagonists in preclinical models and patient-derived systems
- Exploring the use of biomarkers to stratify patients for targeted therapeutic interventions and enhanced clinical outcomes

Roundtable Moderator:



Paul Kayne
Vice President,
Biological Sciences
Palatin Technologies

2.00 Roundtable Discussion: Advancing Autoimmune Therapeutics: Precision Approaches to Inflammation

- Which emerging targets do you see as most promising for transforming the treatment of autoimmune and inflammatory diseases
- What are the key hurdles to validating novel targets, clinically?
- Where do you see the most opportunity to combine precision medicine tools (e.g. multi-omics, digital pathology, AI) with new target exploration to drive better outcomes in autoimmune disease?



Paul Kayne
Vice President,
Biological Sciences
Palatin Technologies

2.30 Inflammatory Resolution of Ulcerative Colitis – The Melanocortin System

- Melanocortin agonists don't block the immune system, they promote resolution of inflammation
- Animal studies demonstrate the effectiveness and mechanisms of action of these agonists
- A Phase 2 clinical study showed 33% remission vs 0% placebo and 78% clinical response vs 33% placebo



Paul Kayne
Vice President,
Biological Sciences
Palatin Technologies

3.00 Chair's Closing Remarks

3.05 End of 3rd Precision Medicine in Inflammatory Bowel Disease Summit

🗨️ It was an intimate meeting with excellent representation from big pharma and biotech in the IBD space. I was able to have meaningful conversations with most attendees whether through round table discussions or social breaks 🗨️

Past Speaker, Associate Director of Immunology, **Takeda**

Partner With Us



Precision Medicine in Inflammatory
Bowel Disease Summit
May 13-15, 2025 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Expertise Partner

Powering quantum leaps in human health. nference partners with health systems to transform decades of rich and predominantly unstructured data captured in electronic medical records (EMR) into powerful software solutions that enable scientists to discover and develop the next-generation of personalized diagnostics and treatments for patients worldwide.

www.nference.com



Innovation Partner

Perspectum is a global medical imaging company delivering innovative solutions for clinical trials. Taking a holistic approach to inflammatory bowel diseases, the company leverages advanced digital pathology and endoscopy solutions. Our end-to-end solution covers the entire reading workflow—from site to final report—delivering faster, more accurate endpoint assessments. Our platform is customizable to your specific protocol requirements, eliminating workflow inefficiencies while reducing sponsor burden. Perspectum has supported over 75+ trials, demonstrating proven scalability for large-scale clinical studies.

www.perspectum.com/for-professionals/pharma-solutions



Event Partner

Alimentiv is a leading gastroenterology CRO providing tailored clinical trial management, central imaging, precision medicine, and statistical services. Over the past 20 years, Alimentiv has become recognized for providing unmatched end-to-end support for complex IBD trials. As a pioneer in IBD research, Alimentiv leverages cutting-edge multi-omics tissue analytics by offering custom immunostaining, digital image analysis, spatial biology, and bioinformatics services to enable actionable, data-driven insights.

www.alimentiv.com

GET INVOLVED



Eirini Karavasili
Business Development Manager
☎ +1 617 455 4188
@ sponsor@hansonwade.com

Partner With Us



Precision Medicine in Inflammatory
Bowel Disease Summit
May 13-15, 2025 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Forge Strong Connections with Global Leaders in Precision Medicine for IBD

The **3rd Precision Medicine in Inflammatory Bowel Disease Summit** is your premier opportunity to connect with senior decision-makers in immunology, gastroenterology, and precision medicine who are committed to driving innovation and solving challenges in this evolving field.

Join an audience of 80+ senior key opinion leaders actively seeking partnerships in data management, AI/ML, technological innovation, multi-omics sequencing and analysis, biomarker development, and other transformative services. They are eager to connect and collaborate with fellow leaders driving advancements in these fields.



Showcase Your Innovative Technologies & Diagnostic Services to a Targeted Audience of Senior Leaders in Precision Medicine for IBD

Showcase your cutting-edge technologies and diagnostic services to an audience of senior leaders driving unprecedented innovation in precision medicine for IBD. With agenda topics ranging from AI-driven patient stratification to multi-omics analysis, combination therapies, and advanced imaging tools, align your solutions with the most pressing challenges in IBD care. Leverage strategic exposure before, during, and after the summit to demonstrate your impact, foster meaningful partnerships, and solidify your position as a leader transforming outcomes for patients with inflammatory bowel disease.



Gain Strategic Market Insights to Stay Ahead in the Dynamic IBD Landscape


Understand the key priorities of biopharma and precision medicine leaders as they seek innovative tools to improve patient stratification, disease monitoring, and therapeutic outcomes. Position your solutions to meet the latest regulatory requirements and scientific advancements, ensuring you remain a critical partner in advancing care for patients with IBD.



Forge High-Impact Collaborations with Influential Stakeholders from Biopharma, Diagnostics, & Academic Institutions

Participate in dedicated networking opportunities, including speed networking and targeted discussions, to build valuable partnerships that drive progress in IBD diagnostics and patient care. Collaborate with leaders sharing a common goal of advancing precision medicine and improving outcomes for patients with inflammatory bowel disease.


TYPES OF COMPANIES ATTENDING*



Drug Developer
Academic/Research Institutes
Service Provider

*Statistics Taken from the 2nd Precision Medicine in Inflammatory Bowel Disease Summit

SENIORITY OF ATTENDEES*



C-Level: 15%

Director/Head: 30%

President/
Vice President: 16%

Manager/Scientist: 21%

Professor/Other: 18%

GET INVOLVED



Eirini Karavasili
Business Development Manager
☎ +1 617 455 4188
@ sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book



www.precision-medicine-in-ibd.com/take-part/register



Tel: +1 617 455 4188



Email: info@hansonwade.com



DISCOVER how leading companies are leveraging groundbreaking technologies and multi-omics approaches to address the complexity of inflammatory bowel disease and advance next-generation precision therapeutics



BUILD your understanding of the challenges, strategies, and solutions to improve patient stratification, biomarker development, and therapeutic efficacy in IBD



CONNECT with your peers and community from leading pharma, biotech, and academic institutions to forge lasting connections, foster meaningful collaborations, and identify the best solutions for advancing precision medicine in IBD

Drug Developer Pricing*	Standard Pricing	On The Door
Conference + Focus Day	\$4,097 (Save \$100)	\$4,197
Conference Only	\$2,899 (Save \$100)	\$2,999
Academic & Not-for-Profit Pricing**	Standard Pricing	On The Door
Conference + Focus Day	\$3,497 (Save \$100)	\$3,597
Conference Only	\$2,499 (Save \$100)	\$2,599
Service & Solution Provider Pricing	Standard Pricing	On The Door
Conference + Focus Day	\$4,997 (Save \$100)	\$5,097
Conference Only	\$3,599 (Save \$100)	\$3,699

*To qualify for the drug developer rate your company must have a public drug pipeline, and not provide pay-for services to any other company. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for the academic and research rate you must be full time academic or employee of a not-for-profit organization. Please visit the website for full pricing options or email info@hansonwade.com


Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: info@hansonwade.com



Venue

Revere Hotel Boston Common
200 Stuart Street, Boston, MA 02116, United States
www.reverehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom



+1 617 455 4188

@ info@hansonwade.com

www.precision-medicine-in-ibd.com

[Companion Diagnostics](#)



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE